1 completed, 1 unknown. 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Agyany Pharma LTD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3) Ambroxol - Gaucher Disease, Type 3 | Not applicable | Completed | Agyany Pharma LTD | 12 | 2025-03-01 | 2026-08-24 |
| High-Dose Ambroxol in GBA1-Related Parkinson Ambroxol Hydrochloride - Parkinson Disease, GBA Gene Mutation | Phase 1 / Phase 2 | Unknown | Agyany Pharma LTD | 40 | 2023-10-24 | 2024-02-08 |
Ataxia (1) · Gaucher Disease (1) · Lysosomal Storage Diseases (1) · Myoclonus (1) · Neurologic Manifestations (1) · Parkinson Disease (1)
Ambroxol (1)
Israel (1) · Pakistan (1)
Ari Zimran, MD (1) · Huma Arshad Cheema, Prof. (1)